Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Vasogen-- VAS on TSE -- Ignore unavailable to you. Want to Upgrade?

To: jackil_54 who wrote (196)	9/3/1999 7:19:00 PM
From: David Michaud	Respond to of 377

It's likely a back to bio-tech rally. VAS offers big value at 2.00 Long overdue

To: jackil_54 who wrote (196)	9/3/1999 8:15:00 PM
From: Syncrude	Read Replies (2) \| Respond to of 377

jackil 54, I suspect that the recent buying has indeed been from people who have never heard of Vasogen before. Thus there might be some weakness, between now and the Sept 28 (?) presentation to be given by the company. I don't think that anyone has disputed the potential of Vasogen's technology. Rather people have been discouraged by the endless field trials that were followed by....more field trials. Don't forget that the stock had declined quite a lot and the recent price is not necessarily indicative of the potential. Volume in the past months has been low, so I don't know about accumulation. Vasogen is at a critical point of their development. They can't be issuing shares for research forever. PS. Investor's Digest is simply a collection of articles by different authors and brokerage firms. Vasogen has been recommended by an Investor's Digest columnist for ages now, Phil Speller. Always predicting great things for Vasogen, but it just has not happened. Id doubt that his editorials would have any impact on demand.